Skip to content

Sellas Life Sciences

US · SLS #2687 by market cap Listed 1970
13.66 -1.20 -8.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:58

Recent news

  • Company notice
    SLS BIO Co: Other Management Information(Voluntary Disclosure) (상장폐지결정 등 효력정지 가처분 신청)
    OPENDART · 2026/10/26
  • Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/7/9
  • Rating change
    Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/5/15
  • Company notice
    Sims Ltd: Appointment of Tiffany Osias as President of SLS
    ASX · 2026/11/5
  • Rating change
    Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/3/14
  • Company notice
    Solstice Minerals Ltd: Application for quotation of securities - SLS
    ASX · 2026/11/6
  • Rating change
    A. G. P. Initiates Sellas Life Sciences(SLS.US) With Buy Rating, Announces Target Price $25
    Market Newswire · 2026/7/6
  • Rating change
    Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4
    Market Newswire · 2025/2/22
  • Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, Vs. FactSet Est of $0.05 Loss
    MT Newswires · 2026/8/12
  • Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/15
  • Rating change
    A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7.5
    Market Newswire · 2025/11/18
  • Rating change
    Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Maze Therapeutics, Inc. (MAZE)
    TipRanks · 2025/12/31
  • Rating change
    Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7
    Market Newswire · 2025/12/31
  • SLS Bio to Be Delisted From KOSDAQ on Nov. 5 Following KRX Review
    MT Newswires · 2026/10/26
  • Company notice
    SLS BIO Co: Suspension of Stock Trading (투자자 보호)
    OPENDART · 2026/10/26
  • Rating change
    A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/3/20
  • Company notice
    Syra Health Corp. | 3: Initial statement of beneficial ownership of securities-10% Owner SLS GROUP LLC
    SEC · 2023/9/29
  • Rating change
    A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/5/13
  • Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold Surge
    Zhitong Finance · 2026/11/12
  • Company notice
    SLS BIO Co: Termination of Suspension of Stock Trading (상장폐지에 따른 정리매매 개시)
    OPENDART · 2026/10/23
  • Company notice
    Sims Ltd: SLS Investor Day Presentation
    ASX · 2026/9/18
  • Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/10/30
  • Company notice
    Solstice Minerals Ltd: Application for quotation of securities - SLS
    ASX · 2026/9/14
  • Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/20
  • Pre-Market Movement | SLS.US Stock Price Fluctuates Amid Multiple News Items
    Market Newswire · 2026/6/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.

Sellas Life Sciences discussion 0 comments

Add a comment